Key result
Atorvastatin cuts major CV events ~30% vs placebo in older adults without improving disability-free survival.
Why the trial?
Statins are proven for primary prevention in middle age, but healthy adults over 70 were never the subject of a dedicated randomised trial, leaving both the benefit and the effect on disability-free survival uncertain in older people.
Does atorvastatin 40 mg once daily reduce cardiovascular events and improve disability-free survival in community-dwelling adults ≥70 years without prior cardiovascular disease, diabetes, or dementia?
Population
9971 community-dwelling adults >=70 without CVD, diabetes, or dementia
Comparison
Atorvastatin 40 mg daily vs matching placebo
Design
Double-blind placebo-controlled RCT at Australian general practices
Follow-up
Median 5.9 years
Authors
Experts read STAREE as a clear win for statins in healthy adults over 70, shifting the debate to who should be treated rather than whether the drugs work.
Early expert reaction reads STAREE as the randomized answer the field has been waiting for on statins in healthy adults 70 and older. Most clinicians lead with the same two facts: major cardiovascular events fell about 30 percent on atorvastatin 40 mg over a median of 5.9 years, and the second primary endpoint, disability-free survival, did not improve. The live question is what a clear cardiovascular benefit without a longevity gain should change in practice.
Among clinicians discussing the trial, the shared ground is that a real evidence gap just closed. Statins had never been properly tested in people over 70, and STAREE now shows a meaningful reduction in major cardiovascular events in that group (HR 0.70, 95% CI 0.61 to 0.82).
What the split result means at the bedside. The benefit was carried by fewer nonfatal coronary events, with cardiovascular death unchanged and no gain in disability-free survival.
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Whether guidelines for people over 70 will move, and who exactly should start therapy. Clinicians also flag the endpoints that stayed flat: dementia alone (HR 1.03) and the combined endpoint of death, dementia, or persistent disability (HR 0.94).
The benefit was carried by fewer nonfatal coronary events: myocardial infarction and coronary revascularization each fell sharply (HR 0.57) while cardiovascular death was unchanged (HR 1.00). The second primary endpoint, death, dementia, or persistent disability, was neutral (HR 0.94). He supports statins for healthy, community-dwelling older adults, with absolute benefit, frailty, polypharmacy, preferences, and adherence still shaping the decision.
He explains the null mortality result: 80 percent of deaths in STAREE were from non-cardiovascular causes, since these patients mostly die of cancer, infections, and dementia. His three-year view: about 1.4 percent absolute risk reduction, an NNT near 72, no gain in lifespan or disability, a safe profile with no rise in serious adverse events, roughly 30 dollars a year in drug cost, and shared decision making.
An emphatic reaction to the presentation, noting the trial population averaged 74 years old.
Supports statin initiation for CV prevention in adults ≥70 without CVD; confirms event reduction in primary prevention but leaves disability-free survival benefit open.
| Outcome | Atorvastatin | Placebo |
|---|---|---|
| Major CV events (CV death, MI/stroke, revascularization) | 297 (10.9/1000 py) | 412 (15.5/1000 py) |
| Co-primary - HR 0.70 (95% CI 0.61-0.82); P<0.001 | ||
| Death, dementia, or persistent physical disability | 637 (21.6/1000 py) | 676 (23.0/1000 py) |
| Co-primary - HR 0.94 (95% CI 0.84-1.05); P=0.25 - not significant | ||
Safety
Serious adverse events 131 (2.7%) vs 129 (2.7%); musculoskeletal, hepatobiliary, and diabetes-related adverse events were more common with atorvastatin (per-arm counts not reported).
Representation
enrolled only healthy community-dwelling Australians without diabetes or dementia, limiting generalizability to frailer elders.
Statistical certainty
the disability-free survival co-primary was not met, so the benefit is confined to cardiovascular events.
Does atorvastatin 40 mg once daily reduce cardiovascular events and improve disability-free survival in community-dwelling adults ≥70 years without prior cardiovascular disease, diabetes, or dementia?
Hazard Ratio: 0.7 (95% CI 0.61–0.82)
Absolute Event Rate: 10.9% vs 15.5%
p-value: p=<0.001
In older adults without prior cardiovascular disease, atorvastatin 40 mg daily significantly reduced major cardiovascular events but did not extend disability-free survival.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Zoungas et al. (2026) conducted an RCT in Primary prevention of cardiovascular events (n=9,971). Atorvastatin vs. Placebo was evaluated on composite of death from cardiovascular causes, nonfatal myocardial infarction or stroke, or coronary revascularization (HR 0.70, 95% CI 0.61 to 0.82, p=<0.001). Atorvastatin reduced the risk of major cardiovascular events compared to placebo (HR 0.70; 95% CI 0.61-0.82; P<0.001) but did not result in longer disability-free survival in older adults.
Synapse has enriched one closely related paper. Consider it for comparative context:
